A double- blind, randomized, and placebo-controlled clinical trial with omega-3 polyunsaturated fatty acids (OPFA É·-3) for the prevention of migraine in chronic migraine patients using amitriptyline.
Nutr Neurosci
; 21(3): 219-223, 2018 Apr.
Article
in En
| MEDLINE
| ID: mdl-28056704
ABSTRACT
OBJECTIVE:
To determine the prophylactic effect of OPFAÏ-3 in migraine. SUBJECTS ANDMETHODS:
This was a prospective, experimental, controlled, double-blind, and with comparison groups study. Sixty patients diagnosed with chronic migraine, according to the criteria of the International Classification of Headache Disorders, Third Edition (beta version) (ICHD-3ß), were prophylactically treated with amitriptyline. They were divided into two equal groups in group 1, prophylaxis was associated with OPFAÏ-3 and in group 2 with placebo. After 60 days, both groups were assessed by a second researcher.RESULTS:
Of the 60 patients with chronic migraine, only 51 patients (15 men and 36 women) completed the treatment. The group that received OPFAÏ-3 consisted of 27 (52.9%) patients (six men and 21 women), while the control group was equal to 24 (47.1%) patients (nine men and 15 women). These differences were not significant (χ2 = 1.428; P = 0.375). In 66.7% (18/27) of the patients who used OPFAÏ-3, there was a reduction of more than 80.0% per month in the number of days of headache, while in the control group, the same improvement occurred in 33.3% (8/24) of patients. This difference was significant (χ2 = 5.649; P = 0.036).CONCLUSIONS:
Polyunsaturated omega 3 fatty acids (OPFAÏ-3) are useful for prophylaxis of migraine attacks.Key words
Full text:
1
Database:
MEDLINE
Main subject:
Fatty Acids, Omega-3
/
Analgesics, Non-Narcotic
/
Dietary Supplements
/
Chronic Pain
/
Amitriptyline
/
Migraine Disorders
Type of study:
Clinical_trials
/
Etiology_studies
Country/Region as subject:
America do sul
/
Brasil
Language:
En
Journal:
Nutr Neurosci
Year:
2018
Type:
Article
Affiliation country:
Brazil